Background: Psoriasis is a persistent, inflammatory, and proliferative skin disorder. It is distinguished by erythematous plaques coated with silvery scales.

Objectives: Highlight the role of adiponectin and myonectin in psoriasis and metabolic syndrome (MetS) patients

Subjects and methods: This case-control study included 45 cases with different types of psoriasis vulgaris, diagnosed based on typical clinical features, of which 15 cases have metabolic syndrome in addition to psoriasis and another 15 patients have psoriasis without metabolic syndrome. PASI and MSSS were assessed besides adiponectin and myonectin and the association between them was evaluated.

Results: There was significant variation between the groups respecting clinical and laboratory data, metabolic syndrome severity score (MSSS), adiponectin, and myonectin (p<0.05). Adiponectin and myonectin were significantly lower in psoriasis with the metabolic group in comparison to psoriasis without the metabolic group. Both groups had significantly lower adiponectin and amyonectin levels than the control group.

Conclusion: Psoriasis cases are susceptible to dyslipidemia and the basic elements of the metabolic syndrome. This emphasizes the importance of screening all psoriasis cases for related MetS to detect it early and treat it to lower morbidity and mortality. Adiponectin and myonectin levels were remarkably elevated in the control group than in psoriasis patients. Adiponectin and myonectin levels were much elevated in the control group than in psoriasis patients. Regarding psoriasis patients, both were lower in metabolic syndrome patients than those who are free of it. Measuring their levels can serve as a measurement for progression of both psoriasis and MetS